Volociximab
From Self-sufficiency
Revision as of 20:15, 5 August 2010 by 208.116.128.56 (Talk)
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Template:Infobox drug/mab source |
| Target | α5β1 integrin |
| Identifiers | |
| CAS Number | 558480-40-3 |
| ATC code | none |
| Chemical data | |
| Formula | C6434H9942N1706O2040S52 |
| Molar mass | 145.5 kDa[[Script error: No such module "String".]] |
Volociximab (also known as M200) is a chimeric monoclonal antibody jointly developed by PDL BioPharma and Biogen Idec for treatment of a variety of advanced solid tumors. It binds to and inhibits the functional activity of α5β1 integrin.[1]
It is thought to reduce metastases. Early results show potential in renal cell cancers. [ref needed]
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />External links
| 40x30px | This monoclonal antibody-related article is a stub. You can help ssf by expanding it. |
- ↑ Ng, CM; Bai, S; Takimoto, CH; Tang, MT; Tolcher, AW (2009). "Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-alpha(5)beta (1) integrin monoclonal antibody (volociximab) in cancer patients". Cancer chemotherapy and pharmacology. 65: 207. doi:10.1007/s00280-009-1023-8. PMID 19468731.
Categories:
- Pages with script errors
- Drugs that are a monoclonal antibody
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- 2Fix
- Cancer treatments
- Pages with broken file links
- Monoclonal antibody stubs
